Short answer
GeneDx Holdings Corp. (WGS) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results announcement for quarter ended September 30, 2026.
GeneDx Holdings Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announcement for quarter ended September 30, 2026
- Press release and earnings presentation furnished as Exhibits 99.1 and 99.2
- Conference call scheduled to discuss quarterly financial performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $123.1M, up 5% YoY, while exome/genome revenue reached $110.4M, up 12%
- Exome/genome volumes rose 25% to 32,134 tests, with accessions up 28%, supporting continued core-market demand
- Adjusted gross margin expanded to 72% from 70% in Q2, while adjusted net income reached $8.6M
- GAAP net loss widened to $12.3M, with nine-month net loss at $93.4M and operating cash use of $72.0M
- Full-year revenue guidance maintained at $475M-$490M, but volume growth reset to at least 28% and adjusted net income guided to approximately $12M
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 revenue $123.1M, up from $114.4M sequentially, with exome/genome revenue reaching $110.4M
- Exome/genome volume 32,134, up 25% YoY, while accession volume grew 28%, signaling sustained demand
- Adjusted gross margin 71.6%, improving from 70.4% sequentially but below 73.8% prior year
- Adjusted net income $8.6M, versus $0.4M sequentially, while GAAP net loss remained $12.3M
- Full-year adjusted net income guidance raised to approximately $12M, while volume growth guidance narrowed to at least 28%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GeneDx Holdings Corp. 8-K filings
Get the next WGS 8-K as it lands
Follow WGS for push alerts, or ask the research agent what this filing means.